Phosphoric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRB1 ADRB2 ADRB3 CYP11B1 DPP4 FGFR1 FGFR2 FGFR3 FGFR4 HRH1 JAK1 JAK2 JAK3 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT NA OPRD1 OPRK1 OPRM1 P PDGFRB PIK3CD SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SMO TYK2 pol rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

	gene	UniProt	supporting neighbours	confidence
▸	HPRT1	P00492	14/20	0.62

▸	PNP	P00491	3/20	0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL146837	0.95	HPRT1 (0.58)	HPRT1
SCHEMBL7192798	0.94	HPRT1 (0.57)	HPRT1
SCHEMBL7197096	0.94	HPRT1 (0.57)	HPRT1
Water SCHEMBL10414024	0.94	HPRT1 (0.57)	HPRT1
SCHEMBL10508833	0.89	HPRT1 (0.55)	HPRT1
SCHEMBL60176	0.88	HPRT1 (0.54)	HPRT1
SCHEMBL10511442	0.87	HPRT1 (0.53)	HPRT1
Phosphoric Acid SCHEMBL571369	0.86	HPRT1 (0.64)	HPRT1
SCHEMBL571080	0.84	HPRT1 (0.60)	HPRT1
SCHEMBL10920053	0.83	HPRT1 (0.56)	HPRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20130281470-A1	Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases	NOVARTIS AG (CH)	2013-10-24	—	—	US	disclosed
US-20110092458-A1	Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases	NOVARTIS PHARMACEUTICALS CORPORATION	2011-04-21	—	—	US	disclosed
US-7045525-B1	Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases	NOVARTIS AG (CH)	2006-05-16	—	—	US	disclosed
US-20060069108-A1	Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases	NOVARTIS PHARMACEUTICALS CORPORATION	2006-03-30	—	—	US	disclosed
EP-0822817-B1	USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES	NOVARTIS INT PHARM LTD (BM)	2003-07-23	—	—	EP	disclosed
EP-0822817-A1	USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES	SMITHKLINE BEECHAM PLC (GB)	1998-02-11	—	—	EP	disclosed
WO-1996033720-A1	USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES	SMITHKLINE BEECHAM PLC (GB)	1996-10-31	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110092458-A1	Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases	TYMP, PNP, HPRT1	HPRT1 3/4885PNP 2/4885
US-20130281470-A1	Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases	TYMP, PNP, HPRT1	HPRT1 3/4885PNP 2/4885
US-20060069108-A1	Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases	TYMP, PNP, HPRT1	HPRT1 3/4885PNP 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.